A detailed history of China Universal Asset Management Co., Ltd. transactions in Intra Cellular Therapies, Inc. stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 18,613 shares of ITCI stock, worth $1.29 Million. This represents 0.17% of its overall portfolio holdings.

Number of Shares
18,613
Previous 18,613 -0.0%
Holding current value
$1.29 Million
Previous $1.29 Million -0.0%
% of portfolio
0.17%
Previous 0.16%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 29, 2024

BUY
$64.37 - $75.65 $481,487 - $565,862
7,480 Added 67.19%
18,613 $1.29 Million
Q4 2023

May 21, 2024

SELL
$46.37 - $73.65 $346,847 - $550,902
-7,480 Reduced 40.19%
11,133 $797,000
Q4 2023

Jan 23, 2024

BUY
$46.37 - $73.65 $401,935 - $638,398
8,668 Added 351.64%
11,133 $797,000
Q3 2023

May 21, 2024

BUY
$52.09 - $64.1 $62,872 - $77,368
1,207 Added 95.95%
2,465 $128,000
Q3 2023

Oct 30, 2023

BUY
$52.09 - $64.1 $62,872 - $77,368
1,207 Added 95.95%
2,465 $128,000
Q2 2023

May 21, 2024

SELL
$54.67 - $66.44 $1,366 - $1,661
-25 Reduced 1.95%
1,258 $79,000
Q2 2023

Jul 27, 2023

SELL
$54.67 - $66.44 $1,366 - $1,661
-25 Reduced 1.95%
1,258 $80,000
Q1 2023

May 21, 2024

BUY
$43.8 - $56.99 $14,059 - $18,293
321 Added 33.37%
1,283 $69,000
Q1 2023

Apr 27, 2023

BUY
$43.8 - $56.99 $14,059 - $18,293
321 Added 33.37%
1,283 $69,000
Q4 2022

May 21, 2024

SELL
$44.07 - $54.45 $777,879 - $961,096
-17,651 Reduced 94.83%
962 $50,000
Q4 2022

Jan 31, 2023

BUY
$44.07 - $54.45 $3,437 - $4,247
78 Added 8.82%
962 $51,000
Q3 2022

Oct 21, 2022

BUY
$42.7 - $59.99 $37,746 - $53,031
884 New
884 $41,000

Others Institutions Holding ITCI

About Intra-Cellular Therapies, Inc.


  • Ticker ITCI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 94,401,696
  • Market Cap $6.52B
  • Description
  • Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...
More about ITCI
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.